Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Buy and raises the price target from $35 to $39.